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ABSTRACT: The self-assembly of polypeptides into amyloid
structures is associated with a range of increasingly prevalent
neurodegenerative diseases as well as with a select set of
functional processes in biology. The phenomenon of self-
assembly results in species with dramatically diﬀerent sizes,
from small oligomers to large ﬁbrils; however, the kinetic
relationship between these species is challenging to character-
ize. In the case of prion aggregates, these structures can self-
replicate and act as infectious agents. Here we use single
molecule spectroscopy to obtain quantitative information on the oligomer populations formed during aggregation of the yeast
prion protein Ure2. Global analysis of the aggregation kinetics reveals the molecular mechanism underlying oligomer formation
and depletion. Quantitative characterization indicates that the majority of Ure2 oligomers are relatively short-lived, and their rate
of dissociation is much higher than their rate of conversion into growing ﬁbrils. We identify an initial metastable oligomer, which
can subsequently convert into a structurally distinct oligomer, which in turn converts into growing ﬁbrils. We also show that
fragmentation is responsible for the autocatalytic self-replication of Ure2 ﬁbrils, but that preformed ﬁbrils do not promote
oligomer formation, indicating that secondary nucleation of the type observed for peptides and proteins associated with
neurodegenerative disease does not occur at a signiﬁcant rate for Ure2. These results establish a framework for elucidating the
temporal and causal relationship between oligomers and larger ﬁbrillar species in amyloid forming systems, and provide insights
into why functional amyloid systems are not toxic to their host organisms.
■ INTRODUCTION
The self-assembly of soluble proteins into insoluble and highly
structured amyloid ﬁbrils rich in β-sheet structure is associated
with a variety of human disorders, including Alzheimer’s and
Parkinson’s diseases, type II diabetes, and the prion diseases.1,2
In addition, the formation of amyloid ﬁbrils has been found to
be a common or generic property of polypeptide molecules,
and also to be associated with a number of diverse biological
functions in living organisms.1,3 Over the past decade,
oligomeric intermediates that form during the early stages of
amyloid ﬁbril formation or dissociate from mature ﬁbrils have
become of increasing interest4 because such species, rather than
the ﬁbrils, have been shown to be toxic to cells and are now
thought to be the major pathogenic agent in neurodegenerative
disease.1,2,5−7 Understanding the nature and dynamics of the
oligomers is not only of intrinsic interest, but has the potential
to provide a catalyst for the development of therapeutic
strategies for protein misfolding diseases.2,8,9
Conventional biochemical and biophysical methods, such as
the thioﬂavin T (ThT) ﬂuorescence assay,10 circular dichroism
spectroscopy (CD),11 electron microscopy (EM)12 and atomic
force microscopy (AFM)13 measurements, are able to provide
ensemble information about the aggregation kinetics of
amyloidogenic proteins as well as the conformation and
morphology of amyloid ﬁbrils and the intermediate preﬁbrillar
species populated during their formation. The metastable and
heterogeneous nature of protein oligomers, however, limits the
detailed characterization of such preﬁbrillar species. Recently, a
variety of novel approaches have been developed and applied
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for this purpose. Fluorescence correlation spectroscopy, for
example, provides information about the nature and distribu-
tion of species formed in the early stages of ﬁbril formation.14,15
Additionally, mass spectrometry and NMR spectroscopy have
been applied to detect and analyze the properties of oligomers
with a range of diﬀerent structures.16−18 Single molecule
ﬂuorescence spectroscopy, however, oﬀers a particularly
powerful approach for exploring the formation and properties
of oligomers, as it has the ability to investigate individual
molecular species and to reveal conformational dynamics that
may be averaged in the ensemble experiment.19,20 These
techniques have been shown to be able to identify and
characterize the low-populated, heterogeneous and transient
species formed during ﬁbril assembly of several amyloidogenic
proteins.21−25
Ure2 from Saccharomyces cerevisiae is the protein determinant
of the yeast prion state [URE3]26 and provides an important
system for probing amyloid formation and prion propagation.
The Ure2 protein is a dimer in solution; each monomer
contains 354 amino acids and consists of two domains.27,28 The
unstructured and ﬂexible N-terminal domain (residues 1−93) is
primarily responsible for prion conversion and propagation in
vivo and for formation of amyloid ﬁbrils in vitro.29−31 The
globular C-terminal domain (residues 94−354) is similar to
glutathione transferases in structure32,33 and has both
glutathione-dependent peroxidase activity34 and glutaredoxin
activity.35 Ure2 is also a negative regulatory factor of nitrogen
metabolism, as in its native state the protein interacts with the
transcription factor Gln3 and represses the uptake of poor
nitrogen sources.36 Therefore, when Ure2 converts into the
aggregated prion state, Gln3 is released and activates the
expression of the genes related to the metabolism of less
favorable nitrogen sources.
While the aggregated prion form of Ure2 is tolerated by yeast
cells, precursor aggregates of Ure2 are toxic to mammalian
cells,37,38 as are amyloid aggregates of other proteins.39 It is
therefore interesting to study the oligomers formed and the
structural changes occurring during Ure2 ﬁbril formation, and
to compare them to disease-related models. In a previous study
we identiﬁed by AFM preﬁbrillar intermediates of Ure2 with a
range of diﬀerent sizes formed during the aggregation
process.31 A soluble oligomeric species formed during the
early stages of Ure2 aggregation was separated and charac-
terized by biochemical and spectroscopic methods.40 Taken
together, these results suggest a connection between the
population of oligomeric species and the course of Ure2
amyloid assembly into mature ﬁbrils. Theoretical modeling has
previously enabled the kinetic parameters that describe the
growth and breakage of Ure2 ﬁbrils to be deﬁned, allowing the
contribution of individual molecular steps to be correlated with
prion propensity;41 however, data on the oligomeric
populations of Ure2, which would allow this type of
mechanistic analysis to be carried out, have not previously
been available. In the present study, we have applied single
molecule ﬂuorescence resonance energy transfer (smFRET) to
investigate in detail the intermolecular assembly and
aggregation process of Ure2. This approach has enabled
oligomerization during the initial lag phase to be observed,
and two types of Ure2 oligomers with diﬀerent assembly modes
have been identiﬁed. Furthermore, using theoretical analysis
combined with single molecule and ensemble kinetic data, we
describe the formation and depletion pathway of oligomers, and
propose a multistep mechanism for Ure2 ﬁbril formation, in
which initial oligomerization is followed by conformational
conversion to β-sheet-containing oligomers that are then able
to grow to form mature amyloid ﬁbrils.
■ METHODS
Mutant Construction, Protein Expression, Puriﬁcation and
Labeling. The single point cysteine variants (V9C, S53C and S68C)
of Ure2 were obtained by overlapping PCR using a synthetic wild-type
URE2 gene as template42 and ligated into the mini-pRSETa vector. All
the mutants constructed in this study were conﬁrmed by DNA
sequencing. Full-length Ure2 was expressed in E. coli C41(DE3) cells
with a His6-tag and puriﬁed by nickel-aﬃnity chromatography as
described previously.42,43 Puriﬁed Ure2 was dialyzed into 50 mM
Tris−HCl (pH 8.4) buﬀer containing 200 mM NaCl and 500 μM
TCEP at 4 °C. Protein purity was checked by SDS-PAGE, and the
protein concentration was determined by the absorbance at 280 nm
for full-length Ure2 using a molar extinction coeﬃcient of 48,220 M−1
cm−1.42 The details of ﬂuorescence labeling of Ure2 are described in
the Supporting Information (SI) Methods.
Single-Molecule FRET Measurement of Ure2 Oligomers.
SmFRET experiments were carried out using a home-built confocal
microscope or total internal reﬂection ﬂuorescence (TIRF) micro-
scope based on a Nikon Ti-E inverted microscope similar to that
described previously.44 The details of the instrumentation, exper-
imental procedures and data analysis used for confocal smFRET and
TIRF smFRET are described in the SI Methods.
Developing a Model for Kinetic Data Fitting. We set out here
to develop a quantitative model that describes the experimental
observables: the total ﬁbril mass concentration M(t) and the total
oligomer concentration O(t). In addition to M(t) and O(t), the model
explicitly considers the concentration of native state dimeric Ure2
m(t), and of ﬁbrils P(t). In particular, the model describes explicitly the
formation of oligomers through dimer association with rate constant
koligo, their conversion to ﬁbrils with rate constant kc, their destruction
(rate constant kd), and ﬁbril growth and fragmentation (rate constants
k+ and k−, respectively). Addition of further complexity to this coarse-
grained model is in principle readily possible within the master
equation formalism; such additional details, including diﬀerentiating
between multiple structural classes within the oligomer subpopula-
tions, would, however, require further experimental constraints than
are currently available, in order to avoid overﬁtting.45 We used the
Ure2 dimer concentration for m(t) rather than the monomer
concentration, as evidence suggests Ure2 remains in its dimeric form
throughout the aggregation reaction (see Results).
The rate equations for the model can be written as a master
equation:
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where we have left out terms with negligible contributions to the
overall kinetics, such as the eﬀects of nonelongation steps on
monomer depletion.46 Any larger oligomers are expected to form
from growth of smaller oligomers; all oligomers ultimately grow from
the initial interaction of a pair of dimeric Ure2 molecules. The
physically reasonable choice of overall reaction order for oligomer
formation is therefore 2.0. (For further explanation, see SI Methods.)
These equations were solved for early times in the aggregation
process, and the solutions used to derive a ﬁrst-order self-consistent
expression for M(t) (see also SI Methods):
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with A = αk+kc/κ
2(kl + κ), kl = kc + kd, κ = + −k k m2 (0) and α =
koligom(0)
2.
The time-dependent evolution of the oligomer population depends
only on koligo, kl and m(t). In turn, m(t) depends only on κ and A, or κ,
kl, and αk+kc. Overall therefore, the dynamics of the dimer and
oligomer populations depend on the following four combinations of
rate parameters: k+k−, k+kc, kl, and koligo. Moreover the ﬁtted values of
koligo and kl are approximately independent of the values chosen for
k+k− and k+kc, provided that these two parameter combinations give a
reasonable ﬁt to the ﬁbril mass concentration.
Relating Model Rate Constants to Fundamental Reaction
Steps. Experiments indicate that we can resolve the observed
oligomers into two structurally distinct populations, with a low-
FRET oligomer formed initially and subsequently converting into a
high-FRET oligomer, which in turn converts to ﬁbrils. The data are
not, however, suﬃciently detailed to allow a full kinetic analysis to be
carried out on both populations individually. The avoidance of
overﬁtting necessitates, therefore, that we consider together the
diﬀerent structural classes of oligomers, and examine the overall ﬂuxes
that lead to their generation or depletion. We can, however,
incorporate elements of our knowledge of the oligomer subpopula-
tions in the overall interpretation of the results. We did so by
determining how each species contributes to the total oligomer
formation, depletion and conversion rate constants in our coarse-
grained model. The concentration of the later high-FRET oligomer
species changes very little over the time course of the aggregation
reaction compared to that of the earlier low-FRET species, and is
present at signiﬁcantly lower concentrations than the earlier low-FRET
species over the times most relevant to the ﬁtting procedure.
Moreover, we show below that high-FRET oligomers are likely to
be formed from conversion of low-FRET oligomers. Therefore, the
rate constants for total oligomer formation and dissociation obtained
from the ﬁtting process can be interpreted as approximately the rate
constants for low-FRET oligomer formation and dissociation. The rate
constant kc gives the approximate proportionality between the overall
oligomer concentration and the rate of formation of ﬁbrils from
oligomers, and so contains information on both the conversion of low-
FRET to high-FRET oligomers, as well as the conversion of high-
FRET oligomers to ﬁbrils. The concentration data on high-FRET
oligomers indicated that the steady-state approximation is likely to be
valid here, in which case we can explicitly write kc in terms of the rate
constants of a more detailed kinetic model featuring two separate
oligomeric species (see SI Methods). The “conversion” rate constant
would then be proportional to the rate constant for transformation of
low-FRET oligomers to high-FRET oligomers, as well as to the rate
constant for conversion of high-FRET oligomers to ﬁbrillar species.
Fitting the Combined smFRET/ThT Data to the Model. The
ThT component of the data was ﬁtted globally to the analytical
expression for the full time-course ﬁbril concentration to obtain values
for A and κ using the online ﬁtting platform Amyloﬁt.47 Then, the
smFRET component of the data was ﬁtted to our early time
expression for O(t) using Mathematica to give approximate values for
koligo and kl. Having established that kd ≫ kc, we can set kd = kl.
Combining these conclusions with A and κ yields approximate values
for k+k− and k+kc. The availability of these approximate rate constants
as trial parameters enabled a numerical ﬁt of our combined smFRET/
ThT data to eqs 1−4 to be carried out, yielding robust rate constants
and verifying the consistency of our model with the experimental data.
For the ﬁtting of the combined smFRET/ThT data, a ratio of 1.5:1
was chosen for k+k−(S68C):k+k−(V9C) (see Results). For a full
description of the kinetic model and ﬁtting methods, see SI Methods.
■ RESULTS
Single Molecule FRET Measurements Can Monitor the
Formation of Ure2 Oligomers. Since Ure2 has no intrinsic
cysteine residues, single cysteine mutations were introduced to
speciﬁc sites within the Ure2 N-terminal region to allow
covalent linkages to maleimide-functionalized dyes. In order to
avoid perturbing the process of Ure2 ﬁbril formation, we chose
mutation sites that are located near the turn of the β-strand in
the structural models of the Ure2 amyloid ﬁbril core.48 The
residues selected were V9C, S53C and S68C, of which V9C and
S53C are near the N-terminal and C-terminal ends of the ﬁbril
core (Figure 1A), respectively, and should be sensitive reporters
of the conformational changes associated with aggregation. The
formation of ﬁbrils by these derivatives was then monitored
using ThT ﬂuorescence. The results showed that both Ure2
S53C and S68C formed ﬁbrils at essentially the same rate as
that of wild-type Ure2, while V9C formed ﬁbrils more slowly, as
reﬂected in a longer lag time than the wild type (Figure S1A). A
possible reason for this change is that V9 is located in one of
the regions of the prion domain that have been shown to be
important for formation of Ure2 amyloid31 and may indeed
participate in the formation of the ﬁrst β-strand in Ure2
ﬁbrils;49 the source of this diﬀerence in rate is addressed further
in the kinetic analysis below. For the case of the dye-labeled
proteins, ThT assays could not be used because of potential
FRET eﬀects between ThT and the labeled ﬂuorophores; the
kinetics of ﬁbril formation by the labeled proteins were
therefore monitored using turbidity measured at OD400, which
indicates that ﬂuorescence labeling does not signiﬁcantly
perturb the ﬁbril formation rate of the mutants (Figure S1B).
Furthermore, the aggregates formed by these unlabeled and
labeled Ure2 proteins were imaged using transmission electron
microscopy (TEM) and each showed a similar ﬁbrillar
morphology to that of wild-type Ure2 ﬁbrils (Figure S1C).
To check the eﬃciency of ﬁbril formation, we also measured
the fraction of labeled protein in the supernatant and the pellet
by SDS-PAGE after the aggregation reaction reached a plateau,
and most of the soluble protein was found to have converted
Figure 1. Oligomerization of Ure2 monitored by confocal single
molecule FRET. (A) Schematic ﬁgure to indicate the cysteine
mutations and ﬂuorescence labeling sites that were used in this
study, based on a previously suggested structural model of Ure2
ﬁbrils.48 (B) Scheme for smFRET detection of Ure2 oligomers. (C)
The concentration of AF555/AF647 labeled Ure2-S68C oligomers
throughout the aggregation reaction. (D) Ensemble kinetics of the
aggregation of 15 μM (dimeric concentration) unlabeled Ure2-S68C
monitored by ThT ﬂuorescence. All the aggregation reactions were
carried out at 18 °C in an Innova 4230 incubator with shaking at 150
rpm in 50 mM Tris−HCl (pH 8.4) buﬀer containing 200 mM NaCl.
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into the insoluble ﬁbrillar form, with less than 10% of the
protein remaining in the supernatant (Figure S1D). Fluo-
rophore attachment on the sites selected here does not,
therefore, alter the ability of Ure2 to form ﬁbrils or the nature
of the ﬁbrillar products. The self-assembly process of the
ﬂuorophore-labeled Ure2, as monitored by single molecule
ﬂuorescence experiments, can therefore be considered to be the
same as that of unlabeled Ure2. Note that since Ure2 is a highly
stable dimer in solution,42,50 and the dimeric unit of Ure2
seldom dissociates during ﬁbril formation (Figure S2); we
therefore refer to the dimer concentration throughout this
study, unless otherwise stated.
Next we used smFRET, which has been used in studies of
other amyloidogenic proteins22−24 to detect the oligomeric
species formed during the Ure2 ﬁbril formation process. The
soluble oligomer formed between AF555- and AF647-labeled
Ure2 gave well-deﬁned FRET signals and could be detected at
the single molecule level by monitoring coincident bursts in
both donor and acceptor channels when the oligomers diﬀused
across the diﬀraction-limited focus (Figure 1B). The numbers
of selected FRET events were converted to oligomer
concentrations (see SI Methods) and plotted against time
(Figure 1C). Meanwhile, the progress of ﬁbril formation of the
unlabeled Ure2 in bulk solution was monitored by the ThT
ﬂuorescence assay under the same incubation conditions
(Figure 1D). As shown in the smFRET data (Figure 1C), the
number of oligomers rises to its highest level within 5 h, which
occurs during the lag phase of the ensemble ThT curve (Figure
1D), reﬂecting the assembly and increase in the number of
oligomers. After 5 h, the soluble oligomeric species were
observed to decrease in concentration as the Ure2 becomes
sequestered into mature ﬁbrils that are not detected by the
confocal smFRET technique. The decrease in the number of
oligomers corresponds well with the onset of ﬁbril formation
reﬂected in the bulk ThT assay under the same conditions
(Figure 1D).
We assessed the stability of the oligomers formed at diﬀerent
time points by taking an aliquot from the aggregation reaction
and diluting it into buﬀer; we then monitored whether or not
there was any decrease in the smFRET burst rate
corresponding to the detection of individual oligomers during
a 1 h window immediately after dilution. Coverslips were
pretreated with unlabeled protein to avoid adsorption of the
labeled sample onto the surface. We observed by TIRF imaging
that pretreatment of the surface with either BSA or unlabeled
Ure2 was equally eﬀective at suppressing the adsorption of the
ﬂuorescently labeled sample (Figure S3A). However, when the
diluted sample was loaded onto BSA-coated coverslips,
oligomer dissociation was evident by confocal smFRET within
1 h (Figure S3B). In contrast, when we used coverslips
pretreated with unlabeled Ure2, the oligomers remained at a
constant level during the measurement time (Figure S3B−F), a
ﬁnding that can be rationalized by the desorption of unlabeled
protein from the surface into solution, thus stabilizing the
oligomers. Therefore, in order to avoid underestimating
oligomer concentrations, we used coverslips coated with
unlabeled Ure2 when performing smFRET experiments.
These results demonstrate the power of single molecule
techniques for the observation of low populations of oligomers.
It is evident that aggregates of Ure2 form during the lag phase
observed by ThT ﬂuorescence, in agreement with theoretical
modeling.51
SmFRET Measurements Reveal the Absence of
Signiﬁcant Oligomer Formation via Secondary Nuclea-
tion During Ure2 Fibril Formation. The two generic
mechanisms that lead to the formation of ﬁbrils are the
primary nucleation pathway, during which new oligomers are
generated by the direct association of soluble protein or peptide
molecules, and secondary pathways, where existing ﬁbrils have
the propensity to generate the formation of new ﬁbrils, either
through fragmentation or through surface catalyzed secondary
nucleation. In the latter case, nucleation of new ﬁbrils takes
place on, and is catalyzed by, the surface of existing ﬁbrils,46 the
rate of which therefore depends on the mass concentration of
existing ﬁbrils. In the case of Aβ42 aggregation,52 whose
kinetics are dominated by the surface-catalyzed secondary
Figure 2. Absence of a ﬁbril-catalyzed secondary nucleation process for Ure2. (A, B) Ensemble aggregation kinetics of 15 μM unlabeled Ure2-S68C
monitored by ThT ﬂuorescence under unseeded (blue) or seeded (red) conditions (upper panels). Ure2 oligomers were then detected under
unseeded (blue) or seeded (red) conditions by confocal single molecule FRET (lower panels). The incubation conditions were the same as in Figure
1. (A) The data ﬁt well to a model that generates oligomers during primary nucleation. (B) A model that generates oligomers during secondary
nucleation cannot ﬁt the data. (C) The presence of seeds (right-hand columns) drastically increases the concentration of Aβ42 oligomers measured at
a single time point in the lag phase of an Aβ42 aggregation experiment52 (right panel), but do not increase the production of Ure2 oligomers in this
study (lef t panel), indicating fundamentally diﬀerent mechanisms of oligomer formation for these two systems.
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nucleation pathway, it has been shown explicitly that the
majority of small oligomers present during the reaction are
produced during secondary nucleation.52 In earlier studies of
Ure2, we have shown that fragmentation events are important
determinants of the rate of ﬁbril formation under both
quiescent and shaking conditions41,53,54 although the produc-
tion of oligomers through surface-catalyzed secondary
nucleation in the case of Ure2 has not previously been
discounted.
We measured the generation of Ure2 oligomers directly
using smFRET in the presence of 1% preformed mature ﬁbrils
to provide a surface for oligomer formation if secondary
nucleation were to occur at a signiﬁcant rate for Ure2. The time
course of oligomerization observed by smFRET in the presence
of the added ﬁbrils shows a similar initial rate to that of the
unseeded system, and the quantity of oligomers detected at
each time point is not increased, indicating that the rate of
oligomer production during secondary nucleation is insignif-
icant compared to the rate of direct association of dimers to
form oligomers during primary nucleation. This was conﬁrmed
by explicit ﬁtting to kinetic models featuring oligomer
formation during primary nucleation (Figure 2A) and during
secondary nucleation (Figure 2B). The former yields a good ﬁt;
the latter a poor ﬁt, a result that is very diﬀerent from the
ﬁndings for Aβ4252 (Figure 2C). The quantity of Ure2
oligomers under seeded conditions appears to be lower than
in the absence of preformed ﬁbrils, which is likely to be a result
of the rapid depletion of native Ure2 by association with, and
elongation of, the pre-existing ﬁbril ends. Together with the
kinetic analysis of the ensemble ﬁbril formation of Ure2 (SI
Methods and Figure S4), this observation conﬁrms that the
proliferation of Ure2 ﬁbrils results from fragmentation and not
from secondary nucleation.
Analysis of Oligomer Populations Reveals the
Existence of an Oligomer Conformational Conversion
Step. The results so far have established that Ure2 oligomers
are formed predominantly from the free association of dimers
during primary nucleation. We can demonstrate using the
following simple argument that only a minority of these
oligomers ultimately become ﬁbrils, and that both an oligomer
dissociation pathway and a conformational conversion step are
needed. Taking a conservative estimate of the initial oligomer
formation rate of 20 nM/h (Figure 1C), and noting that
minimal native Ure2 depletion occurs over the ﬁrst 4 h of
aggregation, a concentration of oligomers of at least 80 nM will
be formed in the ﬁrst 4 h. The rate of oligomer formation
declines subsequently, but does not cease until all Ure2 is
depleted from solution at ∼10−12 h; we therefore estimate the
lower bound on the total concentration of oligomers that form
during primary nucleation to be 100 nM. Mature Ure2 ﬁbrils
are observed to have lengths typically greater than 100 nm, and
mostly on the micrometer scale. Given that the interchain
distance within an amyloid ﬁbril is ca. 0.5 nm, ﬁbrils must
typically contain at least 100 Ure2 dimers. In the smFRET
experiments the concentration of Ure2 dimers incorporated
into ﬁbrils is approximately 15 μM, so the ﬁnal concentration of
ﬁbrils is at most 150 nM. Ure2 has also been shown to follow
fragmentation-dominant kinetics, so ﬁbril formation through
primary nucleation is insigniﬁcant compared to the total
formation of ﬁbrils through fragmentation. The total
concentration of ﬁbrils formed through primary nucleation
must therefore be at least an order of magnitude less than the
total concentration of ﬁbrils formed, and so is signiﬁcantly less
than 15 nM. This value is far lower than the concentration of
oligomers formed during primary nucleation observed in our
smFRET experiments, and leads us to conclude that most
oligomers must dissociate rather than elongate. Given that
oligomers undergo faster dissociation than the ﬁbrils, the
oligomers must be structurally distinct from ﬁbrils. In the
following two sections we demonstrate that new ﬁbrils are
likely to originate from structural conversion of these
oligomers, although this must occur much more slowly than
dissociation. This result was conﬁrmed by comparing ﬁtted
values for the oligomer conversion and dissociation rate
constants (see kinetic analysis below).
Two Types of Oligomeric Species with Diﬀerent
Structures Can Be Observed. To investigate directly the
possibility of structurally distinct subpopulations of Ure2
oligomers, potentially related by additional conformational
conversion steps, we performed an smFRET eﬃciency
distribution analysis. Here we used S53C rather than S68C
Ure2, because both these variants show similar ﬁbril formation
kinetics to the wild-type protein, but the S53 residue is closer to
the ﬁbril core than is S68 and is thus expected to be more
sensitive to structural changes within the oligomers. The
experiment was carried out in a similar manner to that
described above except that AF488 instead of AF555 was used
to label Ure2 in order to reduce cross talk between the donor
and acceptor ﬂuorophore in the smFRET experiments, allowing
detection of population distributions not apparent when using
the AF555 dye as donor. We calculated the FRET eﬃciency of
selected oligomers at diﬀerent time points during ﬁbril
formation to obtain a FRET eﬃciency distribution histogram
(Figure 3). At the early stages within the lag time, for example
after 1 h of aggregation in the case of S53C, only one broad,
low FRET eﬃciency distribution with a maximum of 0.40 was
observed. As the aggregation reaction progressed, but before
signiﬁcant ﬁbril mass had formed, an additional higher FRET
eﬃciency distribution with a maximum of 0.68 appeared,
Figure 3. Diﬀerent types of Ure2 oligomers revealed by confocal single
molecule FRET. (A,B) SmFRET eﬃciency distribution of selected
oligomers of AF488/AF647-labeled Ure2 at diﬀerent incubation times.
The FRET distributions at diﬀerent time points were ﬁtted globally to
double Gaussian functions giving the average peak positions indicated.
(C,D) Population of low- and high-FRET oligomers of Ure2 at
diﬀerent incubation times. The incubation conditions were the same as
in Figure 1. (A,C) Ure2-S53C. (B,D) Ure2-V9C.
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suggesting these later oligomers contain a more compact
assembly of Ure2 molecules than the initial low-FRET
oligomers (Figure 3A). Despite the slow kinetics of ﬁbril
formation, the existence of two diﬀerent types of oligomers was
also observed for the V9C mutant (Figure 3B), where the low
and high FRET distributions peaked at 0.46 and 0.66,
respectively. High-FRET oligomers appear after low-FRET
oligomers but before ﬁbrils, suggesting that they are formed by
conversion of the low-FRET oligomers. Additionally, the lack
of an increase in the later high-FRET oligomer population as
the ﬁbrils start to form indicates that there is no signiﬁcant
production of surface-catalyzed secondary nuclei (Figure
3C,D). It should be noted that FRET eﬃciency is not only
related to the distance between the donor and acceptor but also
to their dipole orientation. The similar change in the FRET
eﬃciency when dyes were introduced at diﬀerent sites (i.e.,
S53C and V9C) indicates that the signal reﬂects principally the
change in the average distances between dyes, and not the
change of orientation of dyes, as there is little probability of the
latter occurring simultaneously at two diﬀerent residue sites.
An interesting ﬁnding in our smFRET study is the
observation of a lower FRET eﬃciency for the initially formed
oligomers for S53C than for V9C but a similar FRET eﬃciency
of the late phase oligomers for the two variants. This
observation provides clues as to the structures of the two
types of oligomers. Since the V9 residue is located in the
hydrophobic region (residues 9−21) of the N-terminal domain
and the S53 residue is in the Q/N rich region (residues 44 to
80), the closer intermolecular distances within the early stage
oligomers of V9C than S53C strongly suggests that the initial
intermolecular oligomerization involves hydrophobic interac-
tions. After the reorganization of the initial oligomers to β-
sheet-containing oligomers, both V9 and S53 sites would be
included in the amyloid structure and should have similar
interchain distances between the same residues aligned along
the ﬁbril axis, thus explaining the similarity of the
intermolecular FRET eﬃciency of the late phase oligomers
(the high-FRET species) of the two mutants.
To obtain further evidence to support the coexistence and
interconversion of two types of oligomers, we carried out a dot
blot assay using the conformation-speciﬁc antibodies A11 and
OC that have been used previously for identiﬁcation of speciﬁc
types of oligomers.55,56 We ﬁrst probed the two types of
oligomers formed during aggregation of full-length Ure2, but
the signals obtained in the experiments were very weak,
probably caused by the blocking eﬀect of the globular C-
terminal domain surrounding the N-terminal prion domain of
Ure2. Therefore, we used the N-terminal prion domain
fragment (residues 1−93) to perform the dot blot assay (see
SI Methods). The results (Figure S5) show that two types of
oligomers exist during aggregation of the Ure2 prion domain
and that the concentration of relatively disordered oligomers
(A11 reactive species) reaches a maximum earlier than the β-
sheet rich oligomers (OC reactive species), indicating a
possible conversion from the former to the latter, consistent
with our conclusions based on the smFRET results. Taken
together, these results indicate that the two oligomeric
intermediates have distinct structural properties, consistent
with the existence of a conformational conversion step between
the earlier and later appearing oligomers.
Ure2 Oligomers That Disaggregate from Mature
Fibrils Have Structures Similar to Those of the
Oligomers Appearing Later in the Aggregation Reac-
tion. We next probed by smFRET the structures of the Ure2
species dissociated from ﬁbrils. The mature ﬁbrils formed from
an equimolar mixture of AF488-Ure2 and AF647-Ure2 were
incubated in fresh buﬀer for at least 1 h before detection by
confocal smFRET, under the same conditions as for the
aggregation reaction. Upon incubation, the oligomers dissociat-
ing from ﬁbrils reached a concentration of 0.1−0.2% of the total
Ure2 ﬁbril mass concentration, the same proportion as
observed in the combined smFRET/ThT data set at the end
of the aggregation reaction. These oligomers showed a broad
FRET distribution, mainly between 0.2 and 0.8, and could not
be precisely ﬁtted by a Gaussian function due to the extremely
low occurrence of such species. In order to detect large or
insoluble species, which may not be observed during the
confocal smFRET experiment, we applied TIRF with smFRET
to probe the dissociated oligomers in order to increase the
detection eﬃciency for larger species (see SI Methods). In
addition, in order to obtain a higher number of disaggregated
oligomers, we sonicated the AF488/AF647 ﬁbrils before
carrying out the smFRET measurements. The resulting mixture
of oligomers and small ﬁbrils in TIRF images showed
coincident signals in both AF488 and AF647 channels, and
the FRET distribution of the samples of Ure2 S53C and V9C
could be ﬁtted by double Gaussian functions (Figure 4). Two
major populations centered at around 0.64 and around 0.8 were
observed, the lower of which was similar to the high-FRET
distribution observed during the aggregation reaction (Figure
3), and can be attributed to disaggregated oligomers. The
species showing higher FRET values, with a maximum at
around 0.8, can be attributed to small ﬁbrils, indicating the
more compact structure within amyloid ﬁbrils. This observation
is remarkably similar to that in previous studies of α-
synuclein.22 The results of TIRF experiments, therefore,
demonstrate that the oligomers that disaggregate from Ure2
ﬁbrils have the same structural properties as the oligomeric
species formed in the later stages of the aggregation reaction.
This ﬁnding strongly suggests that the high-FRET oligomers
contain β-sheet structure similar to that found in mature
amyloid ﬁbrils, and that this type of oligomeric species is able to
convert to elongation-competent ﬁbril-type species.
Kinetic Analysis of Combined smFRET and ThT Data
Yields a Quantitative Understanding of Oligomer
Formation, Dissociation and Conversion. Analysis of the
kinetics of the aggregation reaction is a crucial step in
understanding the microscopic mechanism of amyloid for-
mation. Previous theoretical work has provided an analytical
solution to the kinetics of ﬁbril formation involving
Figure 4. Single molecule TIRF measurements of disaggregated ﬁbrils.
(A,B) SmFRET distribution histogram of Ure2 oligomers disaggre-
gated from AF488/AF647-labeled ﬁbrils. Data were ﬁtted to a double
Gaussian function (continuous line) to obtain the FRET values of the
two species. (A) Ure2-S53C. (B) Ure2-V9C.
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fragmentation,57 and by globally ﬁtting the ThT curves over a
range of concentrations58 to this expression, two combined
kinetic parameters, knk+ and k+k− can be obtained, where kn, k+
and k− represent the amyloid nucleation, elongation and
fragmentation rates, respectively. To study how the mutations
aﬀect these rates, and thus to gain further structural and
mechanistic insight into the nucleation process, we performed
smFRET experiments to compare the oligomer formation of
the two Ure2 mutants, V9C and S68C.
Previous kinetic modeling of amyloid aggregation used a
single coarse-grained reaction step to represent the “primary
nucleation” pathway by which new ﬁbrils are generated via an
initial association step. Here, the availability of accurate kinetic
data on the total concentration of oligomeric intermediates
allows us to devise a less coarse-grained kinetic model that
explicitly includes intermediates in the nucleation step. The
model remains partly coarse-grained, however, as it makes no
distinction between diﬀerent oligomer types; nevertheless, it
provides additional insights into the nature of the nucleation
process. In this model, oligomers are formed through an initial
assembly process, occurring with rate constant koligo, and
subsequently convert into growth-competent ﬁbril-type species
with a rate constant kc. These species can then elongate by
dimer addition with rate constant k+, and fragment with rate
constant k−. The oligomers can also dissociate with rate
constant kd (that we have shown above is much larger than kc).
Note that we can approximately interpret oligomerization and
dissociation as fundamental reaction steps; however, the
conversion step is in fact a coarse-grained step that contains
information on the transformation of low-FRET to high-FRET
oligomers, as well as on the subsequent conversion of the latter
species to ﬁbrils (see Methods and SI for full details). The
accurate determination of reaction orders with respect to
dimers requires kinetic data for a range of initial dimer
concentrations. Given just one initial dimer concentration,
however, we can make the reasonable assumption of a reaction
order of 0 for conversion and 2 for oligomer formation. Any
inaccuracy in these reaction orders is eﬀectively incorporated
into our deﬁnitions of kc and koligo, and does not signiﬁcantly
aﬀect the quality of the ﬁtting (see SI Methods).
An accurate analytical solution for the time dependence of
the ﬁbril mass concentration in our model can be derived by
extension of previous approaches.57,59 The solution is identical
to the analytical solution for the kinetics of a fragmenting
system, upon which the kinetic analysis of the bulk ThT
experiments in the SI is based, except that the ﬁbril nucleation
rate knm(0)
nc is resolved in terms of the microscopic processes
introduced in our oligomer model. Speciﬁcally, we obtain
α
κ
=
+ +
k m
k
k k
(0)
( )
n
n
c
c d
c
(6)
where κ = + −k k m2 (0) and α = koligom(0)nc. This result,
combined with an analysis of the equation governing oligomer
kinetics, reveals that the kinetics of this system are controlled
by the parameter combinations koligo, kd, k+kc, and k+k−. The
combined rate parameters k+kc and k+k− can be determined
with order-of-magnitude accuracy.
A numerical procedure was used to ﬁt the combined
smFRET and bulk ThT data to this model (see Methods for
further details). The numerical ﬁts are reasonable given the
accuracy of the data, and show that our coarse-grained model
provides a good description of the system (Figure 5). The
minor divergence between the ﬁtted curve and the data for
S68C oligomers at the latest times is consistent with the fact
that disaggregation from ﬁbrils yields a small population of
oligomers at equilibrium, yet to avoid overﬁtting there is no
explicit ﬁbril disaggregation step in the model. Fitting gives a
value for koligo of 1.6 × 10
−3 μM−1 h−1 for both variants (Figure
5A,B), and a value of kd of 0.60 h
−1 for S68C, and 0.45 h−1 for
V9C. This result indicates that the kinetics of oligomer
formation by S68C and V9C are broadly similar, but that the
S68C oligomers dissociate more readily by a factor of
approximately 1.3. Given that the rates of oligomer formation
are very similar, it is likely that the reaction order of
oligomerization is approximately the same in the two mutants
at this concentration range.
The diﬀerences in k+kc and k+k− between the V9C and S68C
variants are less than an order of magnitude, indicating that
these parameters are similar for both variants. An order-of-
magnitude estimate for k+ of 40 μM
−1 h−1 was obtained from
analysis of the seeded aggregation experiment monitored by
ThT ﬂuorescence (see SI Methods and Figure S7 for details).
Figure 5. Fitting of combined smFRET/ThT data to models indicates
a probable eﬀect of mutations on the dissociation of oligomers, but not
on their formation. (A−C) The bulk aggregation kinetics of 15 μM
unlabeled Ure2-V9C (red) and Ure2-S68C (blue) monitored by ThT
ﬂuorescence (lef t panels) and the concentration of AF555/AF647
labeled Ure2-V9C (red) and Ure2-S68C (blue) oligomers throughout
the aggregation reaction monitored by confocal smFRET (right panels)
were globally ﬁtted to a theoretical model (see Methods) including the
formation, dissociation, and conversion of oligomers, and the
elongation and fragmentation of ﬁbrils. The incubation conditions
were the same as in Figure 1. (A) Allowing both koligo and kd to diﬀer
for each mutant gives good ﬁts, with a mean squared error of 1.54. (B)
If koligo is constrained to be the same for both mutants, the model ﬁts
the data equally well, with a mean squared error of 1.58. (C) If neither
koligo nor kd is allowed to diﬀer, the ﬁt is less good, especially around
the time when the oligomer concentration is at a maximum, with a
mean squared error of 1.87. This result therefore implies that koligo is
the same for the two variants, while the values of kd may diﬀer slightly.
Journal of the American Chemical Society Article
DOI: 10.1021/jacs.7b10439
J. Am. Chem. Soc. 2018, 140, 2493−2503
2499
This value allows us to calculate order-of-magnitude estimates
for k− and kc, of 1 × 10
−4 h−1 and 2 × 10−3 h−1 respectively. We
note that kc is 2 orders of magnitude smaller than kd, as
expected from our analysis of oligomer dissociation. To
estimate the diﬀerences in these parameters between each
variant, we used a ratio k+(S68C):k+(V9C) of 1.5:1, as
indicated by seeded bulk experiments (see SI Methods and
Figure S7), and a ratio k−(S68C):k−(V9C) of 1:1 as indicated
by fragmentation rate measurements (see SI Methods and
Figure S8). This series of steps then allows us to calculate a
ratio kc(S68C):kc(V9C) of 1.4:1. Although this value is rather
sensitive both to experimental error and to errors in the
parameter ratios that are used, it can be interpreted as
demonstrating that the conversion rates are similar, although
possibly somewhat larger in S68C. Taken together, these results
indicate that the V9C mutation decreases the ﬁbril elongation
rate and oligomer dissociation rate, leaving the ﬁbril
fragmentation rate and oligomer formation rate unaﬀected.
Furthermore, they suggest that the oligomer conversion rate
may also be slightly decreased by the V9C mutation.
■ DISCUSSION
We have applied single molecule FRET measurements to
investigate the aggregation behavior of the yeast prion protein
Ure2 and to observe the low populations of transient oligomers
formed during the aggregation reaction that are challenging to
detect by ensemble methods. The single molecule FRET
observations indicate that the majority of the oligomers formed
during the initial step of the nucleation process dissociate back
to the native dimeric state, but a small population of oligomers
undergoes a conformational conversion step leading to
formation of elongation-competent species. Quantitative
analysis of a combination of bulk and single molecule data
has provided detailed information about the rates of the
microscopic kinetic steps in the formation of amyloid ﬁbrils,
and how these rates are altered by point mutations in the prion
domain. Based on our observations, a mechanism has been
proposed for the formation of Ure2 amyloid ﬁbrils in which
native Ure2 forms relatively disordered oligomers, probably
driven by hydrophobic intermolecular interactions, only a small
proportion of which then rearrange to form structurally more
compact β-sheet containing oligomers that are able to convert
further to elongation-competent ﬁbrillar species and grow by
addition of native dimers to form mature amyloid ﬁbrils (Figure
6).
Primary nucleation of amyloidogenic proteins, in which a
native protein converts into an elongation-competent species, is
a crucial step in ﬁbril formation. Molecular simulations of the
aggregation of Aβ42 indicate that primary nucleation occurs via
intermediate disordered non-β oligomers, which not only
facilitates encounters between the monomeric proteins but also
provides an environment that facilitates their conversion to
ﬁbrillar β-structure.60,61 Nonspeciﬁc intermolecular interac-
tions, such as hydrophobic interactions, play a crucial role in
the formation of the initial disordered oligomers,60 while the
intra- and intermolecular hydrogen bonding within β-sheets is
considered to be the driving force for the subsequent
conformational conversion.62 This formation of hydrogen
bonds compensates for the disruption of the hydrophobic
interactions in the initial disordered oligomers, thus favoring
conformational reorganization to β-sheet structure in order to
reach the lowest energy state. The conformational reorganiza-
tion between early relatively disordered oligomers and β-rich
elongation-competent species during amyloid formation has
also been suggested by experimental studies of other
amyloidogenic proteins such as α-synuclein,22 Aβ40,63 and
the yeast prion protein Sup35.64 In agreement with theoretical
and experimental results for other amyloid proteins, both
theoretical analysis of oligomer concentrations and direct
observation of two types of Ure2 oligomers possessing diﬀerent
assembly and emergence times (Figure 3) provide additional
evidence for the oligomerization/conversion model as a generic
feature of amyloid nucleation.
In order to obtain a quantitative understanding of the
fundamental reaction steps that contribute to the amyloid
formation process, analytical methods have been used to
describe ﬁbril growth and to obtain the microscopic kinetic
parameters.46,57 Since the advent of single molecule techniques,
it has become feasible to probe the nucleation process directly
in real time throughout the aggregation reaction.22−25
However, the kinetic analysis in previous studies has either
focused on the early stage of oligomer formation22,25 or made
use of a highly coarse-grained nucleated polymerization model
in which secondary processes were not considered and in which
the ﬁtted rate constants were diﬃcult to relate to speciﬁc
reaction steps.24 In this study, we provide a kinetic analysis of
the combined single molecule FRET and ensemble ThT data
(Figure 5 and Figure 2) that considers not only the oligomer
formation process but also the elongation and fragmentation
processes, providing quantitative information about the
complete aggregation pathway of an amyloid protein. Another
advance in the present study is the determination of an
expression for the bulk primary nucleation rate kn, which is
found to depend not only on the rate constants of oligomer
formation, dissociation and conversion, but also on the rate
constants for ﬁbril elongation and fragmentation. Global
analysis of the oligomer formation kinetics, measured by
smFRET, and the ﬁbril formation kinetics, monitored by the
ensemble ThT assay, results in two independent parameters
koligo and kd and two combined parameters kck+ and k+k−, where
the latter two can be decomposed by direct measurement of k+
or of k−. Thus, the theoretical analysis of the smFRET data
provides detailed quantitative information about the funda-
mental steps in the process of amyloid nucleation.
Our study also provides new structural insights into the
aggregation mechanism of Ure2. The disordered N-terminal
domain consists of a hydrophobic region (residues 15−42) and
two Q/N repeat regions (residues 1−14 and 43−89).31 In a
Figure 6. Proposed model for the aggregation pathway of Ure2. Native
dimeric Ure2 forms relatively disordered oligomers driven by
hydrophobic interactions and either dissociates back to the native
state or undergoes conformational conversion to form more compact
oligomers containing β-sheet structure, which can in turn convert into
growth-competent ﬁbrillar species. Fragmentation of ﬁbrils then
contributes to their proliferation.
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previous study, we have demonstrated that deletion of residues
1−42 eliminates the ability of Ure2 to form ﬁbrils at measurable
rates, while deletion of either residues 1−14 or residues 15−42
increases the lag time signiﬁcantly,31 indicating the importance
of this region in the aggregation reaction. We observed that the
V9C mutation causes an increase in the length of the lag phase
for ﬁbril formation compared with that of wild-type Ure2.
Kinetic analysis of the bulk ThT variable-concentration data
under both unseeded and cross-seeded conditions reveals that
this eﬀect is predominantly due to a decrease in the elongation
rate caused by the V9C mutation. We then investigated the
eﬀect of the mutation on the nucleation process in detail by
kinetic analysis of the combined smFRET and bulk ThT data.
The rates of both oligomer dissociation and oligomer
conversion are slightly decreased in the V9C mutant relative
to WT Ure2, while the rate of oligomer formation is unaﬀected,
indicating that V9C forms a more stable oligomer. However,
the V9C mutation has a negligible eﬀect on the overall rate of
formation of elongation-competent oligomers (kn). Taken
together, these results show that the V9 residue plays an
important role in the elongation of Ure2 ﬁbrils, consistent with
a recent structural study using site-directed spin labeling and
electron paramagnetic resonance (EPR), which demonstrated
that the residues 8−12 form the ﬁrst β-strand in the ﬁbrils.49
The toxicity of amyloid oligomers has been demonstrated to
be correlated with the degree of exposure of hydrophobic
surface.65,66 Since oligomers assembled by functional amyloido-
genic proteins, such as Ure2 in this study, and Sup35 in a
previous study,64 have similar conformational features (for
example, reactivity with A11 and OC antibodies) and a similar
formation and conversion pathway to that of toxic amyloido-
genic proteins such as α-synuclein22 and Aβ,60,63 the diﬀerence
between functional and disease-related amyloid remains to be
elucidated. In this study, we observed a gradual decrease in the
concentration of oligomers accompanying the onset of ThT
ﬂuorescence. Calculations and theoretical analysis of the
smFRET data has led to the conclusion that the majority of
Ure2 oligomers formed do not ultimately become ﬁbrils but are
depleted by dissociation. In contrast, the populations of Aβ40
and α-synuclein oligomers have been observed to follow a
single exponential process and to remain at a signiﬁcant
equilibrium concentration even after all the monomers are
depleted.22,23,25 A possible explanation for the accumulation of
Aβ40 and α-synuclein oligomers is that they convert very
slowly relative to their formation, and become kinetically
trapped once monomers are depleted, as the residual
population of oligomers can no longer grow through monomer
addition into ﬁbrils. Another possible explanation for the
diﬀerence is that the ﬁbrils of Aβ40 and α-synuclein may not be
as stable as the Ure2 ﬁbrils, such that the equilibrium between
oligomers and ﬁbrils favors oligomers to a much greater extent
than is the case with Ure2. In either of the above cases, Aβ40
and α-synuclein oligomers should have higher stability relative
to the native state than Ure2 oligomers, and therefore would
not be expected to dissociate signiﬁcantly. The accumulation of
relatively high concentrations of oligomers formed by disease-
related amyloidogenic proteins could therefore be the cause of
their toxicity.
A further potential reason for the higher toxicity of disease-
related amyloidogenic proteins is that oligomers are generated
not only during primary nucleation but also during secondary
nucleation. For the case of Ure2, we have been able to
demonstrate directly the lack of formation of surface-catalyzed
secondary nuclei using smFRET measurements (Figure 2).
Several structural studies indicate that the N-terminal domain
of Ure2 forms an in-register parallel β-sheet structure with its
C-terminal domain decorating the ﬁbril core.67,68 Compared
with other amyloidogenic proteins which show monomer-
dependent secondary nucleation, such as Aβ42,52 α-synuclein69
and IAPP,70 the surface of Ure2 ﬁbrils is likely to be blocked by
the presence of its C-terminal globular domain, thus restricting
the access of native Ure2 to the ﬁbrillar structure and inhibiting
the ability of the pre-existing aggregates to catalyze the
nucleation of the native protein. The absence of surface-
catalyzed secondary nucleation will greatly reduce the
generation of oligomers,52 which is another possible reason
for the lower toxicity of functional amyloids. Taken together,
the low stability of Ure2 oligomers and the absence of
secondary nucleation suggests that the functional yeast prions
may replicate and propagate by fragmentation rather than
secondary nucleation and hence avoid signiﬁcant populations of
potentially toxic oligomers, as occurs in the aggregation of
neurodegenerative disease-related proteins. This study paves
the way for the detailed study and comparison of further
examples of both disease-related and functional amyloid
systems, particularly the variety of amyloidogenic proteins
that play structural and functional roles in bacteria.71,72 The
understanding gained from such studies will not only shed light
on the mechanisms by which amyloid structures are harnessed
for functional roles, but may also provide clues as to possible
new therapeutic strategies to combat amyloid disease.
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